Duopharma Secures Rights to Distribute HFMD Vaccine
The company plans to launch the EnVAX-A71 vaccine in Malaysia, Singapore, and Brunei following regulatory approval.
Updated on Oct. 15, 2026 in Allergies
Live Poll
Should governments prioritize the approval and distribution of vaccines for common contagious childhood illnesses?
Duopharma Biotech has reached an agreement to exclusively distribute the EnVAX-A71 vaccine for Hand, Foot, and Mouth Disease in Malaysia, Singapore, and Brunei. The partnership with Taiwan-based Enimmune Corporation marks a strategic move to build a presence in the regional preventive healthcare market.
Why it matters
The deal aims to introduce the first approved HFMD vaccine to the Malaysian market while expanding Duopharma's portfolio. Securing the distribution rights allows the company to address a significant public health need for a disease that commonly affects young children.
The EnVAX-A71 vaccine targets the Enterovirus A71 strain which frequently impacts children under age five. The agreement carries a five-year duration from the launch date in each jurisdiction.
The players
Duopharma Biotech
This pharmaceutical company is a major player in the Malaysian healthcare sector with a market valuation of RM1.06 billion.
Enimmune Corporation
Based in Taiwan, this biotechnology firm specializes in the development and manufacturing of medical inoculations.
The details
Duopharma (M) Sdn Bhd will lead marketing and sales efforts while Enimmune provides support for Good Manufacturing Practice assessments. The deal remains subject to obtaining necessary regulatory approval in each of the three distribution countries.
Timeline
October 15, 2026: Duopharma officially announced the vaccine distribution agreement.
The Big Picture
The distribution deal follows rigorous Good Manufacturing Practice standards required for international pharmaceutical trade. This partnership marks a strategic alignment within the regional market to satisfy complex compliance protocols for new vaccine entries.
This development could provide families in the region with their first access to an approved preventative measure against HFMD. The availability of the vaccine depends on successful regulatory filings, which will determine when it can be utilized in clinical settings.
The takeaway
Preventive healthcare initiatives often rely on complex cross-border distribution partnerships to bring new medical technologies to market. Consumers should monitor local health ministry updates regarding the formal approval and eventual availability of the vaccine in their territory.
Further reading
For more on evolving disease prevention, visit the Allergies section.
Source note: This article includes information reported by The Edge Malaysia.
Live Poll
Should governments prioritize the approval and distribution of vaccines for common contagious childhood illnesses?
